Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's

Yaqian Xu1, Jing Yang1, Xinyu Hu2

  • 1Department of Neurology, West China Hospital of Sichuan University, Chengdu, 610041, China.

Journal of Neurology
|April 27, 2016
PubMed

Insights

Gray matter volume reduction in Parkinson's disease (PD) affects frontal, limbic, and temporal regions. This brain change may indicate progression from mild cognitive impairment (PD-MCI) to dementia (PDD).

Area of Science:

  • Neuroimaging and Neurodegeneration
  • Neurology and Cognitive Science

Background:

  • Gray matter volume (GMV) reduction is observed in Parkinson's disease (PD) with mild cognitive impairment (PD-MCI) and dementia (PDD).
  • Previous voxel-based morphometry (VBM) studies show inconsistent findings regarding GMV changes in PD cognitive impairment.

Purpose of the Study:

  • To systematically review and meta-analyze VBM studies assessing GMV differences in PD-MCI vs. PD without cognitive impairment (PD-NCI) and PDD vs. PD without dementia (PDND).
  • To quantitatively evaluate GMV changes associated with cognitive decline in Parkinson's disease.

Main Methods:

  • Systematic search of PubMed and EMBASE databases (January 1995 - December 2015) for whole-brain VBM studies.
  • Meta-analysis using AES-SDM to combine coordinates of significant GMV differences.
  • Inclusion of 5 studies (92 PD-MCI vs. 192 PD-NCI) and 10 studies (168 PDD vs. 233 PDND).

Main Results:

  • PD-MCI patients showed GMV reductions in the left superior temporal lobe, left insula, and left superior frontal lobe compared to PD-NCI.
  • PDD patients exhibited GMV reductions in bilateral superior temporal lobe (extending to hippocampus) and left superior frontal lobe compared to PDND.
  • Disease duration negatively correlated with GMV in the left superior frontal lobe in PDD patients.

Conclusions:

  • GMV reductions in frontal-limbic-temporal regions characterize cognitive decline in Parkinson's disease.
  • Progression from PD-MCI to PDD may be indicated by the development of GMV reduction from unilateral to bilateral in these regions.
  • Hippocampal GMV reduction may not be an early marker for cognitive decline in PD.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K